Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis

Autor: Andrew Blauvelt, Leon Kircik, Kim A. Papp, Eric L. Simpson, Jonathan I. Silverberg, Brian S. Kim, Shawn G. Kwatra, Michael E. Kuligowski, May E. Venturanza, Shaoceng Wei, Jacek C. Szepietowski
Rok vydání: 2022
Předmět:
Zdroj: Journal of the European Academy of Dermatology and Venereology. 37:137-146
ISSN: 1468-3083
0926-9959
DOI: 10.1111/jdv.18571
Popis: Ruxolitinib cream is a topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor.To report timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis (AD), a highly pruritic inflammatory skin disease.Two phase 3 trials (TRuE-AD1 [NCT03745638]/TRuE-AD2 [NCT03745651]) enrolled patients aged ≥12 years with AD for ≥2 years, Investigator's Global Assessment score of 2 or 3, and 3%-20% affected body surface area. Patients (total N = 1249; median age, 32 years) were randomised (2:2:1) to twice daily 0.75% ruxolitinib cream, 1.5% ruxolitinib cream or vehicle cream for 8 weeks of double-blinded treatment. Worst itch was measured using the numerical rating scale (NRS).Significantly more patients who applied ruxolitinib cream (either strength) achieved a ≥2-point itch reduction (NRS2) within approximately 12 h versus vehicle (0.75%/1.5% ruxolitinib cream, 16.3%/13.1%; vehicle, 6.9%; both P 0.05), with further improvements through Week 8 (58.3%/65.1% vs 29.4%; both P 0.0001). A ≥4-point itch reduction (NRS4) was achieved by significantly more patients who applied 0.75%/1.5% ruxolitinib cream versus vehicle by Day 2 (8.9%/11.2% vs 2.1%; P 0.005); higher rates were observed at Week 8 (41.5%/51.5% vs 15.8%; P 0.0001). Median time for the 0.75%/1.5% ruxolitinib cream groups to achieve NRS4 from baseline was 15.0/13.0 days; this endpoint was not reached by the vehicle group.Ruxolitinib cream demonstrated rapid improvement in itch in patients with mild to moderate AD that was sustained for 8 weeks. Significantly more patients applying ruxolitinib cream achieved itch NRS2 within approximately 12 h and itch NRS4 by Day 2 versus vehicle.
Databáze: OpenAIRE
Externí odkaz: